Penumbra, Inc. (NYSE:PEN) is set to announce third quarter earning results on Wednesday 28th October 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, PEN to report 3Q20 loss of $ 0.08 per share.
For the full year, analysts anticipate top line of $ 516.87 million, while looking forward to loss of $ 0.27 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 635.00 million ~ $ 645.00 million
Click Here For More Historical Outlooks Of Penumbra, Inc.
Previous Quarter Performance
Penumbra, Inc. announced loss for the second quarter of $ 0.30 per share, from the revenue of $ 105.11 million. The quarterly revenues fell 19.57 percent compared with the same quarter last year. According to street consensus, PEN was expected to report 2Q20 loss of $ 0.39 per share from revenue of $ 100.76 million. The bottom line results beat street analysts by $ 0.09 or 23.08 percent, at the same time, top line results outshined analysts by $ 4.35 million or 4.32 percent.
Stock Performance
Shares of Penumbra, Inc. traded up $ 2.12 or 0.90 percent on Tuesday, reaching $ 238.83 with volume of 404.00 thousand shares. Penumbra, Inc. has traded high as $ 241.80 and has cracked $ 235.03 on the downward trend
According to the previous trading day, closing price of $ 238.83, representing a 94.34 % increase from the 52 week low of $ 121.80 and a 2.11 % decrease over the 52 week high of $ 241.81.
The company has a market capital of $ 8.62 billion and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 8th September 2020, downgraded by Bank of America to Neutral from Buy rating.
Conference Call
Penumbra, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.penumbrainc.com
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; and aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the JET, ACE and 3D Revascularization Device brands.
